Quantcast
Last updated on April 21, 2014 at 1:20 EDT

Latest TNBC Stories

2014-03-05 23:03:19

TNBC Comprises About 15-20 Percent of All Breast Cancer Diagnoses; Disproportionately Affects Women of African and Hispanic Descent New York, NY (PRWEB) March 05, 2014 Targeted therapies to treat triple negative breast cancer (TNBC), an aggressive, highly-metastatic disease that comprises about 20 percent of breast cancer incidences and which cannot be treated with conventional methods, may soon be realized, say researchers from the Icahn School of Medicine at Mount Sinai. Their study,...

2014-02-24 23:24:03

Grassroots Events Across USA on 3.3.14 Focus on Aggressive But Lesser-known Breast Cancer with Disproportionate Impact on Younger Women, African-American Women and Women with BRCA1 Gene Mutation Norwood, NJ (PRWEB) February 24, 2014 Breast cancer treatments and public awareness have advanced in recent years; however, Triple Negative Breast Cancer (TNBC) lags behind with no targeted treatments for patients and minimal recognition of its existence. With up to 20% of breast cancers...

2014-01-30 23:23:57

Triple Negative Breast Cancer Foundation's Second Annual Campaign on 3-3-14 Supports Survivors, Patients and Research of Lesser-known Breast Cancer Norwood, NJ (PRWEB) January 30, 2014 Kicking off a national campaign of grassroots, online and community events, The Triple Negative Breast Cancer Foundation (http://www.tnbcfoundation.org) announced its Second Annual Triple Negative Breast Cancer Day (http://tnbcfoundation.org/tnbcday2014) will be held on Monday, March 3, 2014 — with...

2013-12-12 20:24:56

Mutational status and protein analysis both key to better understanding possible treatment implications for difficult-to-treat disease IRVING, Texas, Dec. 12, 2013 /PRNewswire/ -- Caris Life Sciences®, a leading biosciences company focused on fulfilling the promise of personalized medicine, presented a breast cancer study at the 2013 CTCR-AACR San Antonio Breast Cancer Symposium held this week in San Antonio, Texas. The analysis focuses on identifying potentially actionable therapeutic...

2013-07-26 16:20:02

Singapore, July 27, 2013 - (ACN Newswire) - Scientists at A*STAR's Genome Institute of Singapore (GIS) led in a study that has identified genes that are potential targets for therapeutic drugs against aggressive breast cancer. These findings were reported in the July 2013 issue of PNAS. Out of the 1.5 million women diagnosed with breast cancer in the world annually, nearly one in seven of these is classified as triple negative. Patients with triple- negative breast cancer (TNBC) have tumours...

2012-12-06 08:26:18

CARLSBAD, Calif., Dec. 6, 2012 /PRNewswire/ -- Whole genome sequencing has revealed previously unreported mutations in metastatic triple-negative breast cancer (TNBC), according to a study published by the journal Molecular Cancer Therapeutics. The study, "Genome and transcriptome sequencing in prospective triple negative breast cancer uncovers therapeutic vulnerabilities," was sponsored by the Translational Genomics Research Institute (TGen) and US Oncology Research with support from Life...

2012-11-26 08:23:55

ROCKVILLE, Md., Nov. 26, 2012 /PRNewswire/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing targeted therapeutics for the treatment of cancer, announced today the publication of favorable results of a preclinical study in breast cancer of its oral Aurora A/angiogenic kinase inhibitor, ENMD-2076. (Logo: http://photos.prnewswire.com/prnh/20010620/ENMDLOGO ) The article, entitled "Predictive Biomarkers of Sensitivity to the Aurora and...